WASHINGTON — The United States Food and Drug Administration (FDA) has ordered new warnings about a rare but serious eye condition to be added to the labeling of some of the world's most widely used weight-loss and diabetes medicines, telling patients and healthcare providers on Monday that the drugs may carry a potential increased risk of sudden vision loss.
The medicines affected are the glucagon-like peptide-1 (GLP-1) drugs: Eli Lilly's Mounjaro and Zepbound, and Novo Nordisk's Ozempic and Wegovy. The FDA said it is requiring the new information to appear in the "warnings and precautions" section of the labeling for these drugs, alerting doctors and patients to the potential increased risk of non-arteritic anterior ischemic optic neuropathy, known as NAION.
NAION is a condition in which blood flow to the front part of the optic nerve is reduced, damaging the nerve that carries visual signals from the eye to the brain. It is a common cause of sudden, painless vision loss and can, in some cases, lead to permanent impairment of sight. The underlying cause of the condition is not completely understood.
Illustration: GLP-1 injection pens on a pharmacy shelf. The FDA is requiring new eye-risk warnings on the labeling of drugs such as Ozempic, Wegovy, Mounjaro and Zepbound.
What Happened
On Monday, the FDA informed patients and healthcare providers of the potential increased risk of NAION linked to GLP-1 drugs used for weight loss and diabetes, and said it is requiring the drugs to carry new information about that risk in the warnings and precautions section of their labeling.
The labeling change applies to GLP-1 medicines including Mounjaro and Zepbound, made by Eli Lilly, and Ozempic and Wegovy, made by Novo Nordisk. The warnings and precautions section is the part of the official prescribing information where regulators require manufacturers to flag safety concerns that doctors should weigh and patients should know about before starting treatment.
According to Reuters, which reported the FDA's announcement on Monday, the agency evaluated clinical trial data, animal data, and post-marketing data, including observational studies and case reports, before deciding to require the new warning.
The FDA's action does not remove the drugs from the market, and it does not tell patients to stop taking them. A labeling warning is a regulatory step that sits between taking no action and restricting a medicine: it puts the risk on the record, requires doctors to discuss it, and gives patients the information they need to watch for symptoms and seek help quickly if they occur.
Both drugmakers were asked for comment on the FDA's decision. Eli Lilly and Novo Nordisk did not immediately respond to Reuters' requests for comment, Reuters reported.
The announcement drew a measured reaction from financial analysts who follow the two companies. Citi analyst Geoff Meacham said: "The FDA action may temporarily increase patient and investor concern, but the rarity of NAION and substantial weight, glycemic, cardiovascular, renal, and sleep apnea benefits should preserve a favorable benefit-risk profile and limit changes to prescribing."
That assessment captures the central tension in the FDA's decision. The eye condition at issue is rare, while the drugs are prescribed to very large numbers of people for conditions — type 2 diabetes and obesity — that themselves carry serious health risks.
Background
GLP-1 drugs work by mimicking a hormone the body naturally produces after eating. They slow the emptying of the stomach, reduce appetite, and help the body manage blood sugar, which is why they were first developed to treat type 2 diabetes and were later found to produce substantial weight loss. In a few years, medicines in this class have gone from specialist diabetes treatments to some of the most prescribed — and most discussed — drugs in the world.
NAION itself is not a new condition, and it is not caused only by medicines. It occurs when blood flow to the front part of the optic nerve is reduced, starving the nerve fibers of oxygen and damaging the nerve that carries visual signals from the eye to the brain. It is a common cause of sudden, painless vision loss — "painless" matters, because people may not feel anything wrong until they notice that part of their vision has gone dark or blurred. In some cases the vision loss is permanent. Doctors do not completely understand why NAION happens in any given person.
The link between GLP-1 drugs and NAION first drew serious regulatory attention in Europe. Last year, the safety committee of the European Medicines Agency (EMA) said NAION may affect up to 1 in 10,000 people taking semaglutide — the active ingredient in Wegovy, Ozempic, and Novo Nordisk's other diabetes drug Rybelsus — for at least one year. That statement was the first time a regulator had confirmed the side effect, and it put the risk in quantitative terms: rare, but real enough to be acknowledged in official safety assessments.
Illustration: The optic nerve at the back of the eye. NAION is caused by reduced blood flow to the front part of the optic nerve.
Also last year, four patients in Denmark who experienced vision loss after using Novo Nordisk's GLP-1 drugs were granted compensation, the Danish Patient Compensation authority said. The Danish cases were among the earliest individual reports to be formally recognized, and they helped push the question onto the agendas of regulators beyond Europe.
Research published in 2025 added weight to the concern. A large study published that year tracked nearly 175,000 diabetic patients treated with semaglutide and an equal number of patients taking non-GLP-1 medications for diabetes. It found that the risk of NAION more than doubled after two years of treatment with a GLP-1 drug, compared with diabetes medicines from other classes. A doubling of risk sounds dramatic, but because NAION is rare to begin with, doubling a very small risk still leaves a very small risk — the arithmetic that regulators, doctors, and patients must now work through together.
Readers of this blog will have seen earlier stories about GLP-1 medicines, and this announcement is distinct from each of them. Post #130 (October 21) reported on GLP-1 users stacking unregulated supplements; post #464 (October 28) covered the trial of retatrutide, an experimental drug in the same broad family; post #707 (November 3) compared GLP-1 drugs with metformin for prediabetes; and post #828 (November 5) reported on generic Ozempic in Brazil. None concerned a new FDA labeling requirement or the NAION eye risk. This story is the new regulatory action itself.
Why It Matters
The FDA's decision matters first and foremost because of the sheer number of people who take GLP-1 drugs. Ozempic, Wegovy, Mounjaro, and Zepbound are prescribed for type 2 diabetes and for weight management, and they are taken by people who often have other health conditions as well, including heart disease and kidney disease. When a medicine is used that widely, even a rare side effect can affect a meaningful number of people — and a warning that reaches all of them can prevent harm by prompting earlier recognition of symptoms.
Sudden vision loss is the kind of symptom where speed matters. Because NAION is painless, a person might first notice it on waking, or when part of their field of vision seems missing. A warning on the drug's labeling, and the publicity that accompanies an FDA announcement, increases the chance that a patient who notices such a change will seek urgent eye care rather than waiting to see whether it improves on its own.
The decision also matters for the balance of benefits and risks that doctors discuss with patients. GLP-1 drugs are prescribed because they help control blood sugar and produce weight loss, and those effects in turn reduce the risk of complications of diabetes and obesity. Analyst Geoff Meacham of Citi, quoted above, argued that the substantial weight, glycemic, cardiovascular, renal, and sleep apnea benefits of the drugs should preserve a favorable benefit-risk profile and limit changes to prescribing, even though the FDA's action may temporarily increase patient and investor concern. In other words, the expectation among close watchers of the field is that doctors will keep prescribing these medicines, but will now do so with the eye risk explicitly on the table.
For investors and for the two companies behind the drugs, the labeling change is a reminder that safety monitoring does not end when a drug is approved; it continues for as long as the drug is on the market, and labeling is updated as new evidence emerges.
Illustration: A doctor discussing medication with a patient. Patients should talk to their doctor about any concerns over their treatment.
This article is general information only and is not medical advice. It is based on the FDA's announcement and the sources listed below. If you take a GLP-1 medicine and are concerned about your vision or any other side effect, talk to your doctor or another qualified healthcare professional. Do not stop taking a prescribed medicine without discussing it with your doctor first, and seek urgent medical care if you experience sudden vision loss or any sudden change in your sight.
What Happens Next
The immediate next step is the labeling change itself. The manufacturers will be required to add the new information about the potential increased risk of NAION to the warnings and precautions section of the labeling for the affected GLP-1 drugs. Updated labeling will then be available to doctors and pharmacists through the usual prescribing-information channels, and patient information leaflets may be updated to match.
Doctors, in turn, are likely to begin raising the eye risk with patients who are starting a GLP-1 drug, and with patients already taking one at routine appointments. A doctor will weigh a patient's diabetes or weight-management needs, their other health conditions, and any existing eye problems or risk factors for NAION.
Researchers and regulators will keep watching the evidence. The FDA said it evaluated clinical trial data, animal data, and post-marketing data, and that body of evidence will continue to grow as more studies are published and more case reports are collected. If further research clarifies how large the risk is or which patients are most affected, regulators may update the labeling again.
Attention will also turn to regulators in other countries. The EMA acted last year, and the FDA has now acted; other national regulators may follow with their own labeling changes or safety communications. Patients outside the United States and Europe should watch for announcements from their own medicines regulators, and should raise the question with their doctor if they are taking a GLP-1 drug and have not heard about the warning.
For the companies, the coming weeks will bring questions from doctors, patients, and investors. Eli Lilly and Novo Nordisk did not immediately respond to Reuters' requests for comment on Monday, but both companies can be expected to address the labeling change in their communications with prescribers and in their public statements as the updated labeling is rolled out.
Sponsored: explore today's featured sponsored offers
FAQ
What did the FDA announce about GLP-1 drugs?
The FDA said on November 9, 2026, that GLP-1 drugs for weight loss and diabetes carry a potential increased risk of NAION, a serious eye condition, and it is requiring new information about that risk in the warnings and precautions section of the drugs' labeling.
Which drugs are affected by the new warning?
The warning applies to GLP-1 drugs including Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy. The European regulator's earlier assessment also covered semaglutide, the active ingredient in Wegovy, Ozempic, and Rybelsus.
What is NAION?
NAION, or non-arteritic anterior ischemic optic neuropathy, is caused by reduced blood flow to the front part of the optic nerve. It is a common cause of sudden, painless vision loss and may lead to permanent impairment of sight in some cases.
How common is NAION in people taking these drugs?
It is rare. The European Medicines Agency's safety committee said last year that NAION may affect up to 1 in 10,000 people taking semaglutide for at least one year. A 2025 study found the risk more than doubled after two years of semaglutide treatment, but doubling a very small risk still leaves a very small risk.
Should I stop taking my GLP-1 medicine?
The FDA has not told patients to stop taking these drugs. If you take a GLP-1 medicine and notice sudden vision loss or any sudden change in your sight, seek urgent medical care and talk to your doctor about the new warning.
Sources
- Reuters, "FDA orders new eye warnings for GLP-1 weight-loss drugs over vision-loss risk," November 9, 2026 (reporting by Christy Santhosh and Sneha S K in Bengaluru; editing by Shilpi Majumdar).
- U.S. Food and Drug Administration, safety communication to patients and healthcare providers on the potential increased risk of NAION with GLP-1 drugs, November 9, 2026.
- European Medicines Agency, Pharmacovigilance Risk Assessment Committee, assessment of NAION as a possible side effect of semaglutide, 2025.
- Large observational study of semaglutide and NAION risk in diabetic patients, published 2025, tracking nearly 175,000 patients treated with semaglutide and an equal number taking non-GLP-1 diabetes medications.
- Danish Patient Compensation, compensation decisions for four patients who experienced vision loss after using Novo Nordisk GLP-1 drugs, 2025.
- World News Daily Hub, earlier GLP-1 coverage: post #130 (October 21, 2026), post #464 (October 28, 2026), post #707 (November 3, 2026), post #828 (November 5, 2026).
Comments
Post a Comment